文章名稱引用次數(shù)

• Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes24
• Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials15
• Digital diabetes: Perspectives for diabetes prevention, management and research14
• Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300 U/mL vs glargine 100 U/mL in T2DM11
• A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes10
• Inhibitory role of oxytocin on TNF alpha expression assessed in vitro and in vivo9
• SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes8
• Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement8
• Intensive lifestyle modifications with or without liraglutide 3 mg vs. sleeve gastrectomy: A three-arm non-randomised, controlled, pilot study7
• Trajectories of fasting plasma glucose variability and mortality in type 2 diabetes7